ROUNDTABLE Tissue Engineering and 3D Bioprinting: Is it still Science Fiction?
Saturday, June 3, 2023 11:45 AM - 12:45 PM
Room 242B
Clinic & the Lab
Roundtable
How does patient assessment change in the pediatric space?
Moderator
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Panelists
David G. Lott, MD, Associate Director, Center for Regenerative Biotherapeutics, Mayo Clinic, USA
Doris Taylor, PhD, FACC, FAHA, Associate Director, Center for Regenerative Biotherapeutics, Organamet Bio
Thomas Petersen, MD, PhD, Vice President Regenerative Medicine, United Therapeutics, USA
Session Description
The term for tissue engineering was coined approximately 30 years ago. The goal for decades was to decrease the organ waiting list with greater than 100,000 patients waiting. Where are the opportunities to build organs and tissues? What is the potential of novel biomaterials and cells either as a replacement or to stimulate growth of new tissue. Decellularized organs have the advantage of architecture and factors to fast-track reconstruction. 3D Bioprinting allows recapitulation of the microarchitecture and function of the replacement organ or tissue. Tissue engineering is the smallest investment in the field. What are the hurdles to move these structures to clinical trials and standard of care? Is the dream of building organs to decrease the waiting list still science fiction? This session will do a deep dive into goals to allow this dream to be future reality.
Learning Objectives
Moderator
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Panelists
David G. Lott, MD, Associate Director, Center for Regenerative Biotherapeutics, Mayo Clinic, USA
Doris Taylor, PhD, FACC, FAHA, Associate Director, Center for Regenerative Biotherapeutics, Organamet Bio
Thomas Petersen, MD, PhD, Vice President Regenerative Medicine, United Therapeutics, USA
Session Description
The term for tissue engineering was coined approximately 30 years ago. The goal for decades was to decrease the organ waiting list with greater than 100,000 patients waiting. Where are the opportunities to build organs and tissues? What is the potential of novel biomaterials and cells either as a replacement or to stimulate growth of new tissue. Decellularized organs have the advantage of architecture and factors to fast-track reconstruction. 3D Bioprinting allows recapitulation of the microarchitecture and function of the replacement organ or tissue. Tissue engineering is the smallest investment in the field. What are the hurdles to move these structures to clinical trials and standard of care? Is the dream of building organs to decrease the waiting list still science fiction? This session will do a deep dive into goals to allow this dream to be future reality.
Learning Objectives
- Translation and roadblocks to tissue engineered organs and tissues
- What cells candidates are feasibile for Tissue Engineering
- Consideration for clinical studies with 3D Bioprinting
Julie Allickson
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Moderator
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Moderator
